177Lu-PSMA I&T与177Lu-PSMA-617在转移性去势抵抗性前列腺癌患者中的前列腺特异性膜抗原放射性配体治疗:安全性、生物分布与剂量学的比较
本研究在138例转移性去势抵抗性前列腺癌患者中比较177Lu-PSMA I&T与177Lu-PSMA-617的安全性、动力学与剂量学,发现两者安全性良好,泪腺和腮腺吸收剂量最高但无显著临床后遗症;177Lu-PSMA-617全身和泪腺剂量更高而肾脏剂量更低,肿瘤平均吸收剂量相当,患者间剂量学参数变异大。
要点
- 177Lu-PSMA I&T与177Lu-PSMA-617均显示良好安全性,无急性不良反应及肾毒性。
- 177Lu-PSMA-617全身剂量更高(0.04 vs 0.03 Gy/GBq,P<0.00001)、肾脏剂量更低(0.77 vs 0.92 Gy/GBq,P=0.0015)。
- 泪腺为正常器官中吸收剂量最高者,177Lu-PSMA-617为5.1 Gy/GBq、177Lu-PSMA I&T为3.7 Gy/GBq,但无显著临床后遗症。
核心结论
- 两种177Lu-PSMA放射性配体治疗在转移性去势抵抗性前列腺癌患者中均显示良好安全性,健康器官中泪腺和腮腺吸收剂量最高但未导致显著临床后遗症。
- 177Lu-PSMA-617全身和泪腺吸收剂量更高而肾脏剂量更低,两种药物肿瘤平均吸收剂量相当,剂量学参数患者间变异大,作者认为基于个体患者的剂量学似乎有利于个性化放射性配体治疗。
研究设计与样本
- 本研究共纳入138例经68Ga-PSMA-11 PET/CT证实PSMA表达且病情进展的转移性去势抵抗性前列腺癌患者,平均年龄70±9岁(范围46-90岁)。
- 51例接受177Lu-PSMA I&T 6.1±1.0 GBq(范围3.4-7.6 GBq),87例接受177Lu-PSMA-617 6.5±1.1 GBq(范围3.5-9.0 GBq)。
- 所有患者采用相同方案进行剂量学评估,平均吸收剂量用OLINDA软件(MIRD方案)估算,治疗相关不良事件按美国国家癌症研究所不良事件通用术语标准5.0版分级。
主要发现
- 177Lu-PSMA I&T全身半衰期较短(35 h),177Lu-PSMA-617为42 h。
- 177Lu-PSMA-617全身平均剂量高于177Lu-PSMA I&T(0.04 vs 0.03 Gy/GBq,P<0.00001);尽管177Lu-PSMA-617半衰期更长,其肾脏剂量低于177Lu-PSMA I&T(0.77 vs 0.92 Gy/GBq,P=0.0015)。
- 两种PSMA小分子腮腺剂量相当(0.5 Gy/GBq,P=0.27);所有正常器官中泪腺平均吸收剂量最高,177Lu-PSMA-617为5.1 Gy/GBq、177Lu-PSMA I&T为3.7 Gy/GBq。
- 使用177Lu-PSMA I&T时所有肿瘤转移灶初始摄取均高于177Lu-PSMA-617,肿瘤半衰期更短(P<0.00001);两者肿瘤平均吸收剂量相当(5.8 vs 5.9 Gy/GBq,P=0.96)。
- 所有患者耐受治疗且无急性不良反应;177Lu-PSMA-617和177Lu-PSMA I&T治疗后血红蛋白、白细胞计数和血小板计数出现小幅但统计学显著的下降,无需任何临床干预;两种治疗均未观察到肾毒性。
关键数值与推荐
- 177Lu-PSMA I&T给药活度为6.1±1.0 GBq(范围3.4-7.6 GBq),177Lu-PSMA-617为6.5±1.1 GBq(范围3.5-9.0 GBq)。
- 全身平均剂量:177Lu-PSMA-617 0.04 Gy/GBq vs 177Lu-PSMA I&T 0.03 Gy/GBq(P<0.00001)。
- 肾脏剂量:177Lu-PSMA-617 0.77 Gy/GBq vs 177Lu-PSMA I&T 0.92 Gy/GBq(P=0.0015)。
- 腮腺剂量:两者均为0.5 Gy/GBq(P=0.27)。
- 泪腺平均吸收剂量:177Lu-PSMA-617 5.1 Gy/GBq,177Lu-PSMA I&T 3.7 Gy/GBq;肿瘤平均吸收剂量:177Lu-PSMA I&T 5.8 Gy/GBq vs 177Lu-PSMA-617 5.9 Gy/GBq(P=0.96)。
临床怎么用
- 原文结论指出两种177Lu-PSMA放射性配体治疗在转移性去势抵抗性前列腺癌患者中均显示良好安全性。
- 作者认为基于个体患者的剂量学似乎有利于个性化放射性配体治疗。
局限性
- 原文结论指出剂量学参数存在较大的患者间变异。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective of this study was to determine the safety, kinetics, and dosimetry of the 177Lu-labeled prostate-specific membrane antigen (PSMA) small molecules 177Lu-PSMA I&T and 177Lu-PSMA-617 in a large cohort of patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing PSMA radioligand therapy (PRLT). Methods: In total, 138 patients (mean age, 70 ± 9 y; age range, 46-90 y) with progressive mCRPC and PSMA expression verified by 68Ga-PSMA-11 PET/CT underwent PRLT. Fifty-one patients received 6.1 ± 1.0 GBq (range, 3.4-7.6 GBq) of 177Lu-PSMA I&T, and 87 patients received 6.5 ± 1.1 GBq (range, 3.5-9.0 GBq) of 177Lu-PSMA-617. Dosimetry was performed on all patients using an identical protocol. The mean absorbed doses were estimated with OLINDA software (MIRD Scheme). Treatment-related adverse events were graded according to the Common Terminology Criteria for Adverse Events, version 5.0, of the National Cancer Institute. Results: The whole-body half-lives were shorter for 177Lu-PSMA I&T (35 h) than for 177Lu-PSMA-617 (42 h). The mean whole-body dose of 177Lu-PSMA-617 was higher than that of 177Lu-PSMA I&T (0.04 vs. 0.03 Gy/GBq, P < 0.00001). Despite the longer half-life of 177Lu-PSMA-617, the renal dose was lower for 177Lu-PSMA-617 than for 177Lu-PSMA I&T (0.77 vs. 0.92 Gy/GBq, P = 0.0015). Both PSMA small molecules demonstrated a comparable dose to the parotid glands (0.5 Gy/GBq, P = 0.27). Among all normal organs, the lacrimal glands exhibited the highest mean absorbed doses, 5.1 and 3.7 Gy/GBq, for 177Lu-PSMA-617 and 177Lu-PSMA I&T, respectively. All tumor metastases exhibited a higher initial uptake when using 177Lu-PSMA I&T than when using 177Lu-PSMA-617, as well as a shorter tumor half-life (P < 0.00001). The mean absorbed tumor doses were comparable for both 177Lu-PSMA I&T and 177Lu-PSMA-617 (5.8 vs. 5.9 Gy/GBq, P = 0.96). All patients tolerated the therapy without any acute adverse effects. After 177Lu-PSMA-617 and 177Lu-PSMA I&T, there was a small, statistically significant reduction in hemoglobin, leukocyte counts, and platelet counts that did not need any clinical intervention. No nephrotoxicity was observed after either 177Lu-PSMA I&T or 177Lu-PSMA-617 PRLT. Conclusion: Both 177Lu-PSMA I&T and 177Lu-PSMA-617 PRLT demonstrated favorable safety in mCRPC patients. The highest absorbed doses among healthy organs were in the lacrimal and parotid glands-not, however, resulting in any significant clinical sequel. 177Lu-PSMA-617 demonstrated a higher absorbed dose to the whole-body and lacrimal glands but a lower renal dose than did 177Lu-PSMA I&T. The mean absorbed tumor doses were comparable for both 177Lu-PSMA I&T and 177Lu-PSMA-617. There was a large interpatient variability in the dosimetry parameters. Therefore, individual patient-based dosimetry seems favorable for personalized PRLT.
引用
- Schuchardt C, Zhang J, Kulkarni HR, et al. Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry. J Nucl Med. 2021. PMID: 34887335. doi:10.2967/jnumed.121.262713
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。